The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Pharmacyclics Inc

Nasdaq: PCYC
Last

(U.S.) $139.33

Today's change+0.68 +0.49%
Updated November 26 4:00 PM EST. Delayed by at least 15 minutes.
 

Pharmacyclics Inc

Nasdaq: PCYC
Last

(U.S.) $139.33

Today's change+0.68 +0.49%
Updated November 26 4:00 PM EST. Delayed by at least 15 minutes.

Pharmacyclics Inc up (U.S.)$0.68

Pharmacyclics Inc closed up Wednesday by (U.S.)$0.68 or 0.49% to (U.S.)$139.33. Over the last five days, shares have gained 0.53% and 31.72% year to date. Shares have underperformed the S&P 500 by 2.46% during the last year.

Key company metrics

  • Open(U.S.) $138.99
  • Previous close(U.S.) $138.65
  • High(U.S.) $139.76
  • Low(U.S.) $137.45
  • Bid / Ask-- / --
  • YTD % change+31.72%
  • Volume289,436
  • Average volume (10-day)572,600
  • Average volume (1-month)782,412
  • Average volume (3-month)784,169
  • 52-week range(U.S.) $82.51 to (U.S.) $154.89
  • Beta0.73
  • Trailing P/E127.69×
  • P/E 1 year forward163.35×
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $1.09
Updated November 26 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+15.43%

Based on its net profit margin of 15.43%, Pharmacyclics Inc is less effective than other companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.23%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2014Q2/2014Q1/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014Dec 31, 201312/31/2013
Revenue207113119124
Total other revenue--------
Total revenue207113119124
Gross profit196104113120
Total cost of revenue12964
Total operating expense15915010138
Selling / general / administrative38453540
Research & development44463545
Depreciation / amortization00----
Interest expense (income), net operating--------
Unusual expense (income)655025--
Other operating expenses, total0-----50
Operating income48-371885
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax48-371885
Income after tax41-371864
Income tax, total70021
Net income41-371864
Total adjustments to net income--------
Net income before extra. items41-371864
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items41-371864
Inc. avail. to common incl. extra. items41-371864
Diluted net income41-371864
Dilution adjustment--0----
Diluted weighted average shares78757878
Diluted EPS excluding extraordinary itemsvalue per share0.53-0.490.230.82
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share1.24-0.060.440.82